Effect of recombinant human erythropoietin on the anemia of chronic renal failure |
| |
Authors: | A Urabe F Takaku H Mizoguchi K Kubo K Ota N Shimizu K Tanaka N Mimura H Nihei S Koshikawa |
| |
Affiliation: | Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan. |
| |
Abstract: | Phase I and Phase II studies of recombinant human erythropoietin (rhEpo) were conducted in normal volunteers and in anemic patients with chronic renal failure on maintenance hemodialysis. Three hundred U/person of rhEpo was administered intravenously to healthy normal volunteers in the Phase I study, resulting in no subjective or objective changes. In the Phase II study, 66 patients with chronic renal failure on maintenance hemodialysis with less than 20% hematocrit values were treated with rhEpo in doses of 50 U/kg to 200 U/kg two or three times a week. Hematocrit values increased significantly during the 12 weeks, and the patients' conditions improved. Patients previously requiring blood transfusions became transfusion-independent during our study. There were no obvious side effects, thus indicating the safety and efficacy of rhEpo in the anemia of chronic renal failure. |
| |
Keywords: | |
|
|